PD-1 monoclonal antibody (unspecified)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PD-1 monoclonal antibody (unspecified), covering 2025-08-29 to 2025-08-29. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study [NA]